Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Autores de IIS La Fe

• Jaime Sanz Caballer

  Autor

Participantes ajenos a IIS La Fe

• Nagler, Arnon
• Labopin, Myriam
• Swoboda, Ryszard
• Kulagin, Alexander
• Velardi, Andrea
• Labussiere-Wallet, Helene
• Potter, Victoria
• Kuball, Juergen
• Sica, Simona
• Parovichnikova, Elena
• Bethge, Wolfgang
• Maillard, Natacha
• Platzbecker, Uwe
• Stolzel, Friedrich
• Ciceri, Fabio
• Mohty, Mohamad

Grupos

• Hematología y Hemoterapia

Abstract

Second transplantation (HSCT2) is a potential treatment for primary graft failure (pGF). We assessed the outcome of HSCT2, performed between 2000 and 2021, for pGF in 243 patients with acute leukemia. Median age was 44.8 years. Conditioning at first HSCT (HSCT1) was myeloablative (MAC) in 58.4%. Median time from HSCT1 to HSCT2 was 48 days. Donors for HSCT2 were the same as for HSCT1 in 49%. Engraftment post HSCT2 was achieved by 73.7% of patients. The incidence of acute (a) graft versus host disease (GVHD) grades II-IV and III-IV was 23.2 and 8.1%. 5-year total and extensive chronic (c) GVHD was 22.3 and 10.1%. 5-year nonrelapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS) and GVHD free, relapse-free survival (GRFS) was 51.6, 18.8, 29.6, 30.7 and 22.4%, respectively. Infections were the main cause of death. In multivariable analysis, being transplanted at second vs. first remission, lower Karnofsky performance status (KPS; <90) and receiving MAC at HSCT1 were adverse prognostic factors for NRM, LFS, OS, and GRFS, as was increased age for NRM, LFS, OS. We conclude that HSCT2 can rescue about a third of the patients who experienced pGF, but NRM is as high as 50%.

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

Keywords

• DONOR TRANSPLANTS; PERIPHERAL-BLOOD; UNRELATED DONORS; RELAPSE; REJECTION; SURVIVAL